Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation


Posted January 28, 2016 by MRRSE16

The market presents numerous opportunities for strategic alliances as more than 80 first-in-class products that are in development have not yet entered into any form of co-development or licensing deals

 
Report Description

Albany, New York, April 24, 2015 : Market Research Reports Search Engine (MRRSE) has announced the addition of the ‘ Frontier Pharma: Parkinsons Disease - Identifying and Commercializing First-in-Class Innovation’ report by GBI Research to its rapidly growing market research report database. The report discusses more than 300 therapies for Parkinson’s disease in the pipeline, including over 90 first-in-class therapies. The report segments the pipeline products by phase, molecule type, and therapeutic target.

The report describes the key fact that the mechanism of action of most current and pipeline therapies for Parkinson’s disease is different: most current therapies focus on neuromodulatory receptors, whereas a majority of pipeline products act in a neuroprotective fashion, targeting and eliminating dysfunctional disease processes.

Complete Report with TOC @ http://www.mrrse.com/parkinson-disease-therapeutics-market-report

Scope

Parkinson\'s disease (PD) is a progressive neurological health condition that features a clichéd interplay between a number of pathological processes and features neurodegeneration as one of its key effects. In the U.S. alone, nearly 50,000 - 60,000 new cases of PD are diagnosed every year. Other than these, there are already nearly one million patients of PD in the US and nearly four to six million PD patients in the entire world. It is ranked as the 14th leading cause of death in the US. The exact cause behind PD is not clear. Still, scientists are working towards a cure for the condition and many therapeutic methods are in their developmental phases.

Table of Content

1 Table of Contents 2
2 Executive Summary 5
3 The Case for Innovation 6
4 Clinical and Commercial Landscape 10
5 Assessment of Pipeline Product Innovation 37
6 Signaling Network, Parkinson’s Disease Genetics and Innovation Alignment 46
7 First-in-Class Target and Pipeline Program Evaluation 54
8 Deals and Strategic Consolidations 93
9 Appendix 106

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/131

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Contact
Corporate Office
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States

Tel: +1-518-618-1030
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By MRRSE
Country United States
Categories Business
Tags fragmented market for parkinsons disease , frontier pharma parkinsons disease , parkinsons disease
Last Updated January 28, 2016